Last reviewed · How we verify

Zollinger-Ellison syndrome — Treatment Landscape & Competitive Intelligence

Zollinger-Ellison syndrome (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Zollinger-Ellison syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Nexium esomeprazole AstraZeneca Proton pump inhibitor (PPI) Potassium-transporting ATPase 2001-02-20
Protonix pantoprazole Generic (originally Byk Gulden/Altana/Nycomed) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 2000-02-02
Pantoprazole Sodium Pantoprazole Sodium Pfizer Proton pump inhibitor (PPI) (H+, K+)-ATPase enzyme 2000-01-01
Aciphex rabeprazole Waylis Proton Pump Inhibitor Potassium-transporting ATPase 1999-01-01
Prevacid lansoprazole Generic (originally Takeda) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase 1995-05-10
Prilosec omeprazole AstraZeneca (originally Astra AB) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 1989-09-14
Pepcid famotidine Generic (originally Yamanouchi/Merck) Histamine-2 Receptor Antagonist [EPC] Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2 1986-10-01
Zantac ranitidine GSK (originally Glaxo) H2 receptor antagonist Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor 1983-06-01
Rabeprazole 40 mg rabeprazole-40-mg Pfizer Proton Pump Inhibitor H+/K+ ATPase
Aciphex Aciphex University of Utah Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Zollinger-Ellison syndrome
  2. · 2 drugs in Zollinger-Ellison syndrome
  3. AstraZeneca (originally Astra AB) · 1 drug in Zollinger-Ellison syndrome
  4. GSK (originally Glaxo) · 1 drug in Zollinger-Ellison syndrome
  5. Generic (originally Byk Gulden/Altana/Nycomed) · 1 drug in Zollinger-Ellison syndrome
  6. Generic (originally Takeda) · 1 drug in Zollinger-Ellison syndrome
  7. Generic (originally Yamanouchi/Merck) · 1 drug in Zollinger-Ellison syndrome
  8. Janssen-Cilag, S.A. · 1 drug in Zollinger-Ellison syndrome
  9. Northern Orthopaedic Division, Denmark · 1 drug in Zollinger-Ellison syndrome
  10. RenJi Hospital · 1 drug in Zollinger-Ellison syndrome
  11. University of Utah · 1 drug in Zollinger-Ellison syndrome
  12. Vanderbilt University Medical Center · 1 drug in Zollinger-Ellison syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Zollinger-Ellison syndrome:

Cite this brief

Drug Landscape (2026). Zollinger-Ellison syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/zollinger-ellison-syndrome. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing